explore -WSS

explore

author：hotspot 2025-08-23 08:52:35 - browse：4248

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

WSS

Biogen joins immunology wave with $1.15 billion acquisition of HI

Idaho college killings prosecutors challenge defense's grand jury claims

Dozens dead from Maui wildfires: What we know about the victims

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Investigation reveals sickle cell patients pressured into sterilizations

UnitedHealth argues against case alleging wrongful AI care denials

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

In Memoriam: Notable people who died in 2023

Dozens dead from Maui wildfires: What we know about the victims

Drug repurposing or repositioning? The language matters

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Alkermes shareholders re

ASCO eve: Let’s set the table for this year's meeting

Trump demands the U.S. pay no more for drugs than other countries … again

Judge sides with young activists in first

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Addressing health care workers' trauma can help fight burnout

Wikipedia

Indictment alleges Trump's ex

Mark Cuban is blaming the wrong people for high drug costs

Making the case for fair compensation in clinical trials

Biogen’s boardroom scandal saddles CEO with first crisis

Investigation reveals sickle cell patients pressured into sterilizations

Illumina slashes 2023 revenue projections yet again

knowledge

hotspot

explore

hotspot